Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 444

Results For "IND"

6841 News Found

ANSSI Wellness inaugurates its new spine clinic in Pune
Healthcare | December 06, 2022

ANSSI Wellness inaugurates its new spine clinic in Pune

Asia’s premier and USA-patented, ANSSI Wellness for spinal decompression was launched in Pune


ASG Eye Hospitals opens hospital in Vashi
Healthcare | December 06, 2022

ASG Eye Hospitals opens hospital in Vashi

The new eye hospital in Vashi is ASG’s second in the Mumbai Metropolitan Region (MMR) and the sixth in Maharashtra


Auretics launched herbal cough syrup ‘Sedoril’
News | December 06, 2022

Auretics launched herbal cough syrup ‘Sedoril’

It offers quick relief in various types of Coughs, Colds and Sore Throat,


Zydus receives final approval from USFDA for Estradiol Transdermal System
Drug Approval | December 05, 2022

Zydus receives final approval from USFDA for Estradiol Transdermal System

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad


Merck to present data from Its hematology portfolio ASH meeting
News | December 05, 2022

Merck to present data from Its hematology portfolio ASH meeting

Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers


Jemperli RUBY phase III trial met its primary endpoint
Clinical Trials | December 05, 2022

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival


EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis
News | December 05, 2022

EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis

Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints


Orchid Pharma launches Rs. 500 Cr QIP programme
News | December 02, 2022

Orchid Pharma launches Rs. 500 Cr QIP programme

With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023


Alembic receives USFDA final approval for Diclofenac Sodium Topical Solution USP
Drug Approval | December 02, 2022

Alembic receives USFDA final approval for Diclofenac Sodium Topical Solution USP

Diclofenac Sodium Topical Solution USP, 2% w/w has an estimated market size of US $512 million for twelve months ending Sep 2022 according to IQVIA


Zydus receives final approval from USFDA for Topiramate Extended-Release capsules
Drug Approval | December 02, 2022

Zydus receives final approval from USFDA for Topiramate Extended-Release capsules

Topiramate Extended-Release capsule had annual sales of US $68.8 mn in the United States according to IQVIA data (IQVIA MAT Sep 2022)